StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Wednesday. The firm issued a sell rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Stephens reiterated an equal weight rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Royal Bank of Canada restated a sector perform rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Finally, Barclays increased their target price on Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a report on Friday, June 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Hold and an average price target of $55.65.

Catalent Price Performance

Catalent stock opened at $58.68 on Wednesday. Catalent has a 52 week low of $31.80 and a 52 week high of $60.20. The business has a 50-day simple moving average of $56.21 and a 200 day simple moving average of $55.69. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.62 billion, a price-to-earnings ratio of -9.62, a PEG ratio of 2.41 and a beta of 1.16.

Catalent (NYSE:CTLT) last posted its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. On average, research analysts forecast that Catalent will post -0.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Hedge funds have recently made changes to their positions in the company. Lindbrook Capital LLC increased its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares during the last quarter. GAMMA Investing LLC bought a new stake in Catalent during the fourth quarter worth approximately $33,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent during the second quarter worth approximately $42,000. Mather Group LLC. bought a new stake in Catalent during the first quarter worth approximately $52,000. Finally, Rakuten Securities Inc. bought a new position in shares of Catalent during the fourth quarter valued at approximately $46,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.